###begin article-title 0
Mutual Inhibition between Kaposi's Sarcoma-Associated Herpesvirus and Epstein-Barr Virus Lytic Replication Initiators in Dually-Infected Primary Effusion Lymphoma
###end article-title 0
###begin p 1
Conceived and designed the experiments: LZ DX. Performed the experiments: YJ DX YZ. Analyzed the data: LZ YJ DX YZ. Wrote the paper: LZ.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 56 74 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 76 79 <span type="species:ncbi:10376">EBV</span>
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 164 169 <span type="species:ncbi:9606">human</span>
###xml 278 281 <span type="species:ncbi:10376">EBV</span>
###xml 375 378 <span type="species:ncbi:10376">EBV</span>
###xml 554 557 <span type="species:ncbi:10376">EBV</span>
###xml 578 581 <span type="species:ncbi:10376">EBV</span>
###xml 626 629 <span type="species:ncbi:10376">EBV</span>
Both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) are members of the human gamma herpesvirus family: each is associated with various human cancers. The majority of AIDS-associated primary effusion lymphoma (PEL) are co-infected with both KSHV and EBV. Dually-infected PELs selectively switch from latency to lytic replication of either KSHV or EBV in response to chemical stimuli. KSHV replication and transcription activator (K-RTA) is necessary and sufficient for the switch from KSHV latency to lytic replication, while EBV BZLF1 gene product (EBV-Z) is a critical initiator for induction of EBV lytic replication.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 18 21 <span type="species:ncbi:10376">EBV</span>
###xml 125 128 <span type="species:ncbi:10376">EBV</span>
###xml 161 164 <span type="species:ncbi:10376">EBV</span>
###xml 176 179 <span type="species:ncbi:10376">EBV</span>
###xml 203 206 <span type="species:ncbi:10376">EBV</span>
###xml 333 336 <span type="species:ncbi:10376">EBV</span>
###xml 482 485 <span type="species:ncbi:10376">EBV</span>
###xml 638 641 <span type="species:ncbi:10376">EBV</span>
We show K-RTA and EBV-Z are co-localized and physically interact with each other in dually-infected PELs. K-RTA inhibits the EBV lytic replication by nullifying EBV-Z-mediated EBV lytic gene activation. EBV-Z inhibits KSHV lytic gene expression by blocking K-RTA-mediated transactivations. The physical interaction between K-RTA and EBV-Z are required for the mutual inhibition of the two molecules. The leucine heptapeptide repeat (LR) region in K-RTA and leucine zipper region in EBV-Z are involved in the physical interactions of the two molecules. Finally, initiation of KSHV lytic gene expression is correlated with the reduction of EBV lytic gene expression in the same PEL cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 232 235 232 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e</italic>
###xml 355 358 <span type="species:ncbi:10376">EBV</span>
In this report, how the two viruses interact with each other in dually infected PELs is addressed. Our data may provide a possible mechanism for maintaining viral latency and for selective lytic replication in dually infected PELs, i.e., through mutual inhibition of two critical lytic replication initiators. Our data about putative interactions between EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of PELs.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 323 326 323 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Kieff1">[1]</xref>
###xml 327 330 327 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Pagano2">[5]</xref>
###xml 383 386 383 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Moore1">[6]</xref>
###xml 387 390 387 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Chang2">[8]</xref>
###xml 566 569 566 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Moore1">[6]</xref>
###xml 571 574 571 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-West1">[9]</xref>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Dourmishev1">[10]</xref>
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 20 23 <span type="species:ncbi:10376">EBV</span>
###xml 92 111 <span type="species:ncbi:37296">human herpesvirus 8</span>
###xml 177 183 <span type="species:ncbi:9606">humans</span>
###xml 185 188 <span type="species:ncbi:10376">EBV</span>
Epstein-Barr virus (EBV) and Kaposi sarcoma (KS)-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8), are the two gamma herpesviruses currently identified in humans. EBV infection has been associated with the development of Buikitts' lymphoma (BL), Hodgkin's disease, nasopharyngeal carcinoma and others [1]-[5]. KSHV is believed to be the etiological agent of KS [6]-[8], and is implicated in the pathogenesis of AIDS-associated primary effusion lymphoma (PEL), also called body cavity-based lymphoma (BCBL), and multicentric Castleman's disease [6], [9], [10].
###end p 9
###begin p 10
###xml 364 367 364 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-West1">[9]</xref>
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Dourmishev1">[10]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Sun1">[11]</xref>
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Zhang1">[18]</xref>
###xml 767 771 767 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Wang1">[19]</xref>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Liang2">[24]</xref>
###xml 31 34 <span type="species:ncbi:10376">EBV</span>
Like other herpesviruses, both EBV and KSHV have latency and lytic replication in their life cycles. The switch from latency to lytic gene expression in KSHV requires the expression of KSHV replication and transcription activator (K-RTA, also called RTA or ORF50). K-RTA is apparently necessary and sufficient for the switch from KSHV latency to lytic replication [9], [10]. K-RTA is a sequence-specific DNA-binding protein that regulates gene expression through K-RTA-responsive elements in the transcriptional regulatory regions of different subsequently expressed viral genes [11]-[18]. K-RTA also interacts with other factors to modulate its transcription potential, and some interactions are ctritical for K-RTA-mediated switch from latency to lytic replication [19]-[24].
###end p 10
###begin p 11
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Deng1">[25]</xref>
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Gwack3">[26]</xref>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Lan1">[27]</xref>
###xml 250 254 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Matsumura1">[28]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Chang3">[29]</xref>
###xml 320 323 <span type="species:ncbi:10376">EBV</span>
###xml 350 353 <span type="species:ncbi:10376">EBV</span>
Beyond functioning in initiating viral lytic replication, K-RTA is involved in the induction of cellular IL-6 [25]. K-RTA also blocks p53-mediated apoptosis by competing for binding to CBP [26]. K-RTA might play a role in latency establishment [27], [28]. K-RTA has been shown to enhance CD21 expression, and facilitate EBV infection because CD21 is EBV receptor in B cells [29].
###end p 11
###begin p 12
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Chevallier1">[30]</xref>
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Countryman1">[31]</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Kouzarides1">[32]</xref>
###xml 433 437 433 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Kenney1">[33]</xref>
###xml 438 442 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Lieberman3">[36]</xref>
###xml 731 735 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Manet1">[37]</xref>
###xml 867 871 867 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Feederle1">[38]</xref>
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
###xml 60 63 <span type="species:ncbi:10376">EBV</span>
###xml 84 87 <span type="species:ncbi:10376">EBV</span>
###xml 151 154 <span type="species:ncbi:10376">EBV</span>
###xml 295 298 <span type="species:ncbi:10376">EBV</span>
###xml 479 482 <span type="species:ncbi:10376">EBV</span>
###xml 488 491 <span type="species:ncbi:10376">EBV</span>
###xml 725 728 <span type="species:ncbi:10376">EBV</span>
###xml 747 750 <span type="species:ncbi:10376">EBV</span>
###xml 839 842 <span type="species:ncbi:10376">EBV</span>
EBV lytic replication can be initiated by expression of the EBV BZLF1 gene product (EBV-Z; also referred as BZLF1, Zta, Z, ZEBRA, and EB1) [30], [31]. EBV-Z is a member of the basic leucine zipper (bZIP) family of DNA binding proteins and has a sequence similar to C/EBP, c-Jun, and c-Fos [32]. EBV-Z binds specifically to DNA with multiple specific recognition sequences and activates transcription of both viral and cellular genes [33]-[36]. One important viral gene target of EBV-Z is EBV BRLF1 gene product, E-RTA (also called BRLF1, RTA, R). K-RTA and E-RTA are homologues genes and this family of genes is highly conserved among gamma herpesviruses. E-RTA is coordinately expressed as a bicistronic RNA transcript with EBV-Z [37]. E-RTA and EBV-Z function synergistically at some promoters and are required for the completion of the EBV lytic replication cycle [38].
###end p 12
###begin p 13
###xml 138 142 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Cayrol1">[39]</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Cayrol2">[40]</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Adamson1">[41]</xref>
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Bell1">[42]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Flemington1">[43]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Urier1">[44]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Sakakibara1">[14]</xref>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Deng2">[45]</xref>
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
###xml 57 60 <span type="species:ncbi:10376">EBV</span>
###xml 232 235 <span type="species:ncbi:10376">EBV</span>
EBV-Z has additional activities other than initiation of EBV lytic replication. These include the ability to block cell cycle progression [39], [40] and the disruption of the PML-associated nuclear domain 10 (ND10/PODs) [41], [42]. EBV-Z can also upregulate its own expression, a property called autoregulation [43], [44]. Of note K-RTA also auto-regulates its own expression [14], [45].
###end p 13
###begin p 14
###xml 329 333 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Nador1">[46]</xref>
###xml 436 439 436 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Moore1">[6]</xref>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Dourmishev1">[10]</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Drexler1">[47]</xref>
###xml 69 72 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 422 425 <span type="species:ncbi:10376">EBV</span>
PELs are B-cell non-Hodgkin's lymphomas and most frequently occur in HIV-positive individuals as lymphomatous effusions in the serous cavities without a detectable solid tumor mass. In the setting of AIDS, the clinical course for most of these lymphomas is extremely aggressive, with a mean survival from diagnosis of 5-7 months [46]. While PELs are almost universally KSHV-positive, the majority of PELs have concomitant EBV infection [6], [10], [47].
###end p 14
###begin p 15
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Trivedi1">[48]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Fan1">[49]</xref>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Groves1">[50]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Krithivas1">[51]</xref>
###xml 716 720 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Xu1">[52]</xref>
###xml 102 105 <span type="species:ncbi:10376">EBV</span>
###xml 267 270 <span type="species:ncbi:10376">EBV</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 482 485 <span type="species:ncbi:10376">EBV</span>
###xml 557 560 <span type="species:ncbi:10376">EBV</span>
###xml 582 585 <span type="species:ncbi:10376">EBV</span>
###xml 631 634 <span type="species:ncbi:10376">EBV</span>
###xml 660 663 <span type="species:ncbi:10376">EBV</span>
In order to understand viral contributions to the pathogenesis of PEL, it is important to address how EBV and KSHV interact with each other and affect biological properties of the cell and the viruses. There are apparent interactions between the two viruses in PELs. EBV enhances the tumorigenecity of the dually-infected PELs in SCID mice [48]. Unique sets of cellular genes are expressed in dually-infected, but not single KSHV-infected PELs [49]. KSHV LANA potentially activates EBV latent membrane protein 1 (LMP-1) [50] , but reduces the expression of EBV EBNA-1 and represses EBV EBNA-2 activation [51]. K-RTA may potentiate EBV latency via induction of EBV LMP-1 and uses LMP-1 to curb KSHV lytic replication [52].
###end p 15
###begin p 16
###xml 107 111 107 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Sun2">[12]</xref>
###xml 113 117 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Miller1">[53]</xref>
###xml 445 449 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Sun2">[12]</xref>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Miller1">[53]</xref>
###xml 85 88 <span type="species:ncbi:10376">EBV</span>
###xml 155 158 <span type="species:ncbi:10376">EBV</span>
###xml 406 409 <span type="species:ncbi:10376">EBV</span>
Of particular interest in dually infected PELs is the selective induction of KSHV or EBV lytic replication [12], [53]. BC-1 is a dually infected PEL line. EBV lytic gene expression is activated by 12-O-tetradecanoylphorbol-13-acetate (TPA or phorbol ester). KSHV lytic gene expression is induced by sodium butyrate (butyrate or n-butyrate). However, when both TPA and butyrate are added, KSHV, rather than EBV, is induced into lytic replication [12], [53]. The selective induction of lytic replications of the two herpesviruses points to the importance of viral factors in the decision-making processes of PELs.
###end p 16
###begin p 17
###xml 172 175 <span type="species:ncbi:10376">EBV</span>
In this report, we have examined the potential molecular mechanism behind this selective lytic replication process. We have found that there is a mutual inhibition between EBV-Z and K-RTA. Because of their critical roles of the two molecules in promoting their respective viral lytic replications, our data offer a possible mechanism for dually-infected cells to keep their respective viral latencies and for selective switch from latency to lytic replications.
###end p 17
###begin title 18
Results
###end title 18
###begin title 19
###xml 56 59 <span type="species:ncbi:10376">EBV</span>
K-RTA negatively regulates the lytic gene expression of EBV
###end title 19
###begin p 20
###xml 297 301 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Xu1">[52]</xref>
###xml 532 553 532 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Fujii1">[54]</xref>
###xml 869 873 869 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Gershburg1">[60]</xref>
###xml 991 998 991 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g001">Fig. 1A</xref>
###xml 36 39 <span type="species:ncbi:10376">EBV</span>
###xml 169 172 <span type="species:ncbi:10376">EBV</span>
###xml 288 291 <span type="species:ncbi:10376">EBV</span>
###xml 374 377 <span type="species:ncbi:10376">EBV</span>
###xml 422 425 <span type="species:ncbi:10376">EBV</span>
###xml 471 474 <span type="species:ncbi:10376">EBV</span>
###xml 517 522 <span type="species:ncbi:9606">human</span>
###xml 568 571 <span type="species:ncbi:10376">EBV</span>
###xml 655 658 <span type="species:ncbi:10376">EBV</span>
###xml 715 718 <span type="species:ncbi:10376">EBV</span>
###xml 952 955 <span type="species:ncbi:10376">EBV</span>
###xml 1124 1127 <span type="species:ncbi:10376">EBV</span>
Because of the co-presence KSHV and EBV in a same PEL cell and the selective induction of lytic replication, we suspect that one or more proteins in KSHV might regulate EBV lytic replication process. K-RTA is a good candidate because it is immediate early protein and able to activate an EBV gene [52]. We thus examined if K-RTA affect the induction of lytic replication of EBV. K-RTA was transfected into Akata cells, an EBV+/KSHV- BL line, and the lytic replication of EBV was induced after the treatment with anti-human-IgG (See Materials and Methods for details). EBV BMRF1 is a lytic gene and its product is often called the diffuse component of the EBV-early antigen (EA-D). The essential function of EA-D in EBV lytic replication has been well established and using it as indicator of lytic replication has been widely accepted and appreciated in the field [54]-[60]. Thus, the expression of EA-D protein was determined and used as indicator of EBV lytic replication. As shown in the Fig. 1A, the expression of EA-D was inhibited upon the expression of K-RTA. Of note multiple bands of EA-D are often observed during EBV lytic replication.
###end p 20
###begin title 21
###xml 15 18 <span type="species:ncbi:10376">EBV</span>
K-RTA inhibits EBV lytic gene expression.
###end title 21
###begin p 22
###xml 22 25 <span type="species:ncbi:10376">EBV</span>
###xml 71 74 <span type="species:ncbi:10376">EBV</span>
###xml 151 154 <span type="species:ncbi:10376">EBV</span>
###xml 193 198 <span type="species:ncbi:9606">human</span>
###xml 391 394 <span type="species:ncbi:10376">EBV</span>
###xml 448 451 <span type="species:ncbi:10376">EBV</span>
###xml 547 550 <span type="species:ncbi:10376">EBV</span>
A. K-RTA inhibits the EBV lytic gene expression in Akata cells. Akata (EBV+/KSHV-) cells were transfected with K-RTA or vector plasmid (5 microg DNA). EBV lytic replication was induced by anti-human-IgGs a day later (0, 1, 5, 10 microg/ml). Cell lysates were separated on SDS-PAGE, transferred, and used for western blot analysis. The identity of proteins is as shown. B. K-RTA inhibits the EBV lytic gene expression in AGS-BX11g cells. AGS-BX11g (EBV+/KSHV-) cells were infected with recombinant adenovirus expressing K-RTA or GFP (10 pfu/cell). EBV lytic replication was induced by TPA a day later. Lysates were used for western blot analysis. The same membrane was stripped and reprobed with other antibodies. One representative from three experiments is shown. The identity of proteins is as shown.
###end p 22
###begin p 23
###xml 341 348 341 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g001">Fig. 1B</xref>
###xml 94 97 <span type="species:ncbi:10376">EBV</span>
###xml 285 288 <span type="species:ncbi:10376">EBV</span>
###xml 407 410 <span type="species:ncbi:10376">EBV</span>
###xml 531 534 <span type="species:ncbi:10376">EBV</span>
In addition, we tested if the same phenomenon can be observed in another cell line, AGS-Bx1g (EBV+, KSHV-). These cells were infected by either recombinant adenovirus expressing K-RTA (AdKRTA) or green fluorescent protein (AdGFP). One day after the infection, the lytic replication of EBV was examined by the treatment with TPA. As shown in Fig. 1B, induction of EA-D protein expression and furthermore the EBV lytic replication was inhibited by the expression of K-RTA. These data suggested that K-RTA was a negative regulator of EBV lytic gene expression.
###end p 23
###begin title 24
###xml 27 30 <span type="species:ncbi:10376">EBV</span>
###xml 68 71 <span type="species:ncbi:10376">EBV</span>
K-RTA negatively regulates EBV-Z initiated lytic gene expression of EBV
###end title 24
###begin p 25
###xml 28 31 <span type="species:ncbi:10376">EBV</span>
###xml 69 72 <span type="species:ncbi:10376">EBV</span>
###xml 131 134 <span type="species:ncbi:10376">EBV</span>
###xml 159 162 <span type="species:ncbi:10376">EBV</span>
It is well established that EBV-Z initiates the lytic replication of EBV. We further examined that if K-RTA is able to inhibit the EBV-Z-mediated induction of EBV lytic gene expression.
###end p 25
###begin p 26
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Feederle1">[38]</xref>
###xml 365 371 365 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g002">Fig. 2</xref>
###xml 544 551 544 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g002">Fig. 2A</xref>
###xml 598 605 598 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g002">Fig. 2B</xref>
###xml 688 692 688 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Wang2">[61]</xref>
###xml 693 697 693 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Liu1">[64]</xref>
###xml 872 879 872 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g002">Fig. 2C</xref>
###xml 28 31 <span type="species:ncbi:10376">EBV</span>
###xml 91 94 <span type="species:ncbi:10376">EBV</span>
###xml 113 116 <span type="species:ncbi:10376">EBV</span>
###xml 159 162 <span type="species:ncbi:10376">EBV</span>
###xml 202 205 <span type="species:ncbi:10376">EBV</span>
###xml 314 317 <span type="species:ncbi:10376">EBV</span>
###xml 373 376 <span type="species:ncbi:10376">EBV</span>
###xml 422 425 <span type="species:ncbi:10376">EBV</span>
###xml 623 626 <span type="species:ncbi:10376">EBV</span>
###xml 666 669 <span type="species:ncbi:10376">EBV</span>
###xml 729 732 <span type="species:ncbi:10376">EBV</span>
###xml 936 939 <span type="species:ncbi:10376">EBV</span>
###xml 1114 1117 <span type="species:ncbi:10376">EBV</span>
A serial of cell lines, 293-EBV, BRLF1-KO, and BZLF1-KO, was used for the experiments. 293-EBV harbors wild type EBV genome. BRLF1-KO and BZLF1-KO contain the EBV genome missing BRLF1 (E-RTA) or BZLF1 (EBV-Z) gene respectively [38]. BRLF1-KO was used primarily because expression of EA-D was not very sensitive to EBV-Z expression (data not shown). As shown in the Fig. 2, EBV-Z is able to induce the lytic replication of EBV as indicated by the induction of EA-D protein. However in the presence of K-RTA, the expression of EA-D is inhibited (Fig. 2A). The inhibition is dose-dependent phenomena (Fig. 2B). Interestingly, EBV-Z and E-RTA can synergistically induce EBV lytic replication [61]-[64]. By reducing the expression of EBV-Z with less plasmid in transfection, we could observe the reported synergy and K-RTA was a potent inhibitor of the synergistic activation (Fig. 2C). Essentially the same results can be obtained from 293-EBV and BZLF1-KO cell lines (data not shown). The use of more than one cell lines is to ensure the results are not cell-line dependent. These data suggested that K-RTA inhibited EBV-Z-mediated lytic gene expression.
###end p 26
###begin title 27
###xml 15 18 <span type="species:ncbi:10376">EBV</span>
###xml 30 33 <span type="species:ncbi:10376">EBV</span>
K-RTA inhibits EBV-Z-mediated EBV lytic gene expression.
###end title 27
###begin p 28
###xml 18 21 <span type="species:ncbi:10376">EBV</span>
###xml 33 36 <span type="species:ncbi:10376">EBV</span>
###xml 60 63 <span type="species:ncbi:10376">EBV</span>
###xml 165 168 <span type="species:ncbi:10376">EBV</span>
###xml 417 420 <span type="species:ncbi:10376">EBV</span>
###xml 478 481 <span type="species:ncbi:10376">EBV</span>
###xml 610 613 <span type="species:ncbi:10376">EBV</span>
###xml 793 796 <span type="species:ncbi:10376">EBV</span>
A. K-RTA inhibits EBV-Z-mediated EBV lytic gene expression. EBV-Z expression plasmid (0, 0.1, and 0.2 microg) plus K-RTA (0.2 microg) were transfected into BRLF1KO (EBV+/KSHV-) cells in 6-well plate as shown on the top. Lysates were used for western blot analysis 24 hours later. The same membrane was stripped and reprobed with other antibodies. The identity of proteins is as shown. B. Dose-dependent inhibition of EBV-Z-mediated lytic gene expression by K-RTA. Fix amount of EBV-Z expression plasmid (0.1 microg) plus various amounts of K-RTA (0, 0.05, 0.1, 0.2, 0.4 microg) were transfected into BRLF1-KO (EBV+/KSHV-) cells in 6-well plate as shown on the top. Lysates were used for western blot analysis. Same cell lysates were used. C. K-RTA inhibits the synergistic activation of EA-D. EBV-Z expression plasmid (0.025 microg), E-RTA (0.1 microg), and K-RTA (0.2 microg) were transfected with different combinations into BRLF1-KO cells as shown on the top. The same cell lysates were used for western blot analysis. The identity of proteins is as shown.
###end p 28
###begin title 29
###xml 10 13 <span type="species:ncbi:10376">EBV</span>
K-RTA and EBV-Z physically interact in dually-infected PEL
###end title 29
###begin p 30
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Wang2">[61]</xref>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Liu1">[64]</xref>
###xml 257 261 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Liao1">[22]</xref>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Wang3">[65]</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Izumiya1">[66]</xref>
###xml 367 371 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Wu1">[67]</xref>
###xml 372 376 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Adamson2">[74]</xref>
###xml 74 77 <span type="species:ncbi:10376">EBV</span>
###xml 109 112 <span type="species:ncbi:10376">EBV</span>
###xml 198 201 <span type="species:ncbi:10376">EBV</span>
###xml 282 285 <span type="species:ncbi:10376">EBV</span>
###xml 393 396 <span type="species:ncbi:10376">EBV</span>
Next we examined the potential mechanism for K-RTA-mediated inhibition of EBV lytic replication. Because: 1) EBV-Z and E-RTA interact functionally and physically [61]-[64]; 2) K-RTA and KSHV K8, an EBV-Z homologue, also interact functionally and physically [22], [65], [66]; and 3) EBV-Z and KSHV K8 interact with same cellular genes, such as p53, CBP and C/EBPalpha [67]-[74], we hypothesize EBV-Z and K-RTA interact with each other physically.
###end p 30
###begin p 31
###xml 308 315 308 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3A</xref>
###xml 5 8 <span type="species:ncbi:10376">EBV</span>
###xml 64 67 <span type="species:ncbi:10376">EBV</span>
###xml 198 201 <span type="species:ncbi:10376">EBV</span>
###xml 246 249 <span type="species:ncbi:10376">EBV</span>
###xml 351 354 <span type="species:ncbi:10376">EBV</span>
###xml 412 415 <span type="species:ncbi:10376">EBV</span>
###xml 671 674 <span type="species:ncbi:10376">EBV</span>
###xml 901 904 <span type="species:ncbi:10376">EBV</span>
###xml 933 936 <span type="species:ncbi:10376">EBV</span>
BC1 (EBV+, KSHV+) cells were treated with TPA first to initiate EBV lytic replication and then treated with butyrate for KSHV lytic replication. The cells were fixed and stained with both K-RTA and EBV-Z antibodies. The localization of K-RTA and EBV-Z was examined under confocal microscope. As shown in the Fig. 3A, many cells contain both K-RTA and EBV-Z in the same nuclei (arrows and asters). Some K-RTA and EBV-Z may be co-localized in the same nuclei (see arrows; yellow color in the Panel d); suggesting they might be interacting with each other physically. The high powered versions of the cells are also present at the bottom. However in some of the cells, both EBV-Z and K-RTA are expressed in the same cells but the co-localization is not apparent, possibly due to the fact that one protein is expressed at much higher levels than the other (see asters). Some cells express either K-RTA or EBV-Z (see solid squares). Thus EBV-Z and K-RTA can be co-expressed and co-localized within dually infected cells.
###end p 31
###begin title 32
###xml 10 13 <span type="species:ncbi:10376">EBV</span>
K-RTA and EBV-Z interact with each other in dually infected cells.
###end title 32
###begin p 33
###xml 32 35 <span type="species:ncbi:10376">EBV</span>
###xml 75 78 <span type="species:ncbi:10376">EBV</span>
###xml 223 229 <span type="species:ncbi:9986">rabbit</span>
###xml 235 238 <span type="species:ncbi:10376">EBV</span>
###xml 242 247 <span type="species:ncbi:10090">mouse</span>
###xml 355 358 <span type="species:ncbi:10376">EBV</span>
###xml 490 493 <span type="species:ncbi:10376">EBV</span>
###xml 537 540 <span type="species:ncbi:10376">EBV</span>
###xml 584 587 <span type="species:ncbi:10376">EBV</span>
###xml 778 781 <span type="species:ncbi:10376">EBV</span>
###xml 794 799 <span type="species:ncbi:10090">mouse</span>
###xml 885 891 <span type="species:ncbi:9986">rabbit</span>
A. Co-localization of K-RTA and EBV-Z in dually infected cells. BC1 (KSHV+/EBV+) cells were treated with TPA (10 ng/ml) first for one day and then butyrate (0.5 mM) for another day. Cells were fixed and stained with K-RTA (rabbit) and EBV-Z (mouse) antibodies. Cy5- and Cy2-labeled secondary antibodies were used to distinguish the signals from K-RTA and EBV-Z, respectively. DAPI was used to stain the nuclei. The colors were artificially mounted to facilitate viewing. Red, K-RTA; green, EBV-Z; blue, nuclei; (a)K-RTA signal only; (b) EBV-Z signal only; (c) nuclei only; (d) K-RTA, EBV-Z, and nucleus signals are mixed. The pictures of higher power are shown on the bottom. In Panels B and C, cell extracts from treated BC1 cells were immunoprecipitated (IP) with either anti-EBV-Z or normal mouse serum (Panel B). Cell lysates were also immunoprecipitated with anti-K-RTA or normal rabbit serum (Panel C). The immunoprecipitates were analyzed by Western blot using the indicated antibodies. The whole cell lysates of induced BC1 cells were used as positive controls in Panels B and C. In Panel D, whole cell lysates was used for western blot analyses. The identity of the respective proteins is denoted. n.s., non-specific. Molecular weight (MW) makers are shown on the left in kilo-Dalton (kDa).
###end p 33
###begin p 34
###xml 342 349 342 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3B</xref>
###xml 462 469 462 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3C</xref>
###xml 586 597 586 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3B, 3C</xref>
###xml 657 664 657 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3D</xref>
###xml 117 120 <span type="species:ncbi:10376">EBV</span>
###xml 218 221 <span type="species:ncbi:10376">EBV</span>
###xml 351 354 <span type="species:ncbi:10376">EBV</span>
###xml 447 450 <span type="species:ncbi:10376">EBV</span>
###xml 496 502 <span type="species:ncbi:9986">rabbit</span>
###xml 526 531 <span type="species:ncbi:10090">mouse</span>
###xml 562 565 <span type="species:ncbi:10376">EBV</span>
###xml 641 644 <span type="species:ncbi:10376">EBV</span>
###xml 691 694 <span type="species:ncbi:10376">EBV</span>
Next, the co-immunoprecipitation assays were used for detection of potential physical interactions between K-RTA and EBV-Z in the induced BC-1 cells. Cell lysates were used for immunoprecipitation with either K-RTA or EBV-Z antibody. The immunoprecipitates were then used for western blot analysis with other specific antibodies. As shown in Fig. 3B, EBV-Z antibody could bring down K-RTA protein. In addition, the K-RTA antibody could bring down EBV-Z protein (Fig. 3C). However, neither normal rabbit serum (NRS) nor normal mouse serum (NMS) could precipitate EBV-Z or K-RTA protein (Fig. 3B, 3C). The induced cells express both K-RTA and EBV-Z proteins (Fig. 3D). These data suggest that EBV-Z and K-RTA interact with each other in induced BC1 cells in vivo.
###end p 34
###begin title 35
###xml 17 20 <span type="species:ncbi:10376">EBV</span>
###xml 68 71 <span type="species:ncbi:10376">EBV</span>
Interaction with EBV-Z is required for K-RTA-mediated inhibition of EBV lytic replication
###end title 35
###begin p 36
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Bu1">[75]</xref>
###xml 277 281 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Wang1">[19]</xref>
###xml 283 287 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Liang1">[23]</xref>
###xml 289 293 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Carroll1">[76]</xref>
###xml 295 299 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Wang4">[77]</xref>
###xml 369 376 361 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g004">Fig. 4A</xref>
###xml 724 739 716 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g004">Fig. 4B, and 4C</xref>
###xml 803 810 795 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g004">Fig. 4D</xref>
###xml 51 54 <span type="species:ncbi:10376">EBV</span>
###xml 501 504 <span type="species:ncbi:10376">EBV</span>
###xml 591 594 <span type="species:ncbi:10376">EBV</span>
###xml 663 666 <span type="species:ncbi:10376">EBV</span>
###xml 717 720 <span type="species:ncbi:10376">EBV</span>
###xml 888 891 <span type="species:ncbi:10376">EBV</span>
We suspect that K-RTA may physically interact with EBV-Z through its leucine heptapeptide repeat region (LR) of K-RTA [75]. This region is included within the domain of K-RTA required for interaction with the several cellular proteins such as K-RBP, RBP-Jkappa, and C/EBPalpha [19], [23], [76], [77]. A mutant with the deletion of the region, K-RTA-DLR, was generated (Fig. 4A). The mutant protein is localized predominantly in the nucleus as wild type K-RTA (data not shown). The plasmids expressing EBV-Z, K-RTA and its mutant were transfected into 293T cells, and the interaction between EBV-Z and the mutant K-RTA was examined. While wt K-RTA interacted with EBV-Z properly, the K-RTA-DLR failed to interact with EBV-Z (Fig. 4B, and 4C). The expression of these proteins in 293T cells were similar (Fig. 4D). Thus, the LR region of K-RTA was involved in the physical interaction with EBV-Z.
###end p 36
###begin title 37
###xml 30 33 <span type="species:ncbi:10376">EBV</span>
Interaction between K-RTA and EBV-Z is required for K-RTA-mediated inhibition.
###end title 37
###begin p 38
###xml 426 429 <span type="species:ncbi:10376">EBV</span>
###xml 708 711 <span type="species:ncbi:10376">EBV</span>
###xml 846 849 <span type="species:ncbi:10376">EBV</span>
###xml 886 889 <span type="species:ncbi:10376">EBV</span>
A. Schematic diagram of K-RTA domains and mutants. The DNA binding domain, leucine heptapeptide repeat region (LR), activation domain, and nuclear localization signal (NLS) are shown. The drawing is not on scale. In Panels B, C, and D, 293T cells were transfected with of the designated expression plasmids as shown on the top of the Figure. Cell extracts from these transfected cells were immunoprecipitated with either anti-EBV-Z (Panel B) or anti-K-RTA (Panel C). The immunoprecipitates were analyzed by Western blot (WB) using the indicated antibodies. In Panel D, whole cell lysate was used for western blot analyses. The identity of the respective proteins is denoted. E. Interaction between K-RTA and EBV-Z is required for K-RTA-mediated inhibition. 80 ng of K-RTA or K-RTA-DLR expression plasmids were transfected with various amounts of EBV-Z expression plasmid into BZLF1-KO (EBV+/KSHV-) cells as shown on the top. Lysates were used for western blot analysis 24 hours later. The same membrane was stripped and reprobed with other antibodies. The identity of proteins is as shown.
###end p 38
###begin p 39
###xml 316 323 316 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g004">Fig. 4E</xref>
###xml 66 69 <span type="species:ncbi:10376">EBV</span>
###xml 81 84 <span type="species:ncbi:10376">EBV</span>
###xml 133 136 <span type="species:ncbi:10376">EBV</span>
###xml 192 195 <span type="species:ncbi:10376">EBV</span>
###xml 284 287 <span type="species:ncbi:10376">EBV</span>
###xml 366 369 <span type="species:ncbi:10376">EBV</span>
###xml 371 374 <span type="species:ncbi:10376">EBV</span>
###xml 452 455 <span type="species:ncbi:10376">EBV</span>
###xml 504 507 <span type="species:ncbi:10376">EBV</span>
Whether the physical interaction is involved in the repression of EBV-Z-mediated EBV lytic gene expression was examined in BZLF1-KO (EBV+, KSHV-) cell line. While wt K-RTA was able to repress EBV lytic replication as expected, the K-RTA-DLR mutant failed to inhibit the expression of EBV-Z-mediated EA-D expression (Fig. 4E). Same results can also obtained from 293-EBV (EBV+, KSHV-) cell line (data not shown). Thus, the interaction between K-RTA and EBV-Z was required for K-RTA-mediated inhibition of EBV lytic gene expression.
###end p 39
###begin title 40
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
EBV-Z inhibits the lytic gene expression of KSHV
###end title 40
###begin p 41
###xml 291 312 291 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 342 349 342 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Fig. 5A</xref>
###xml 21 24 <span type="species:ncbi:10376">EBV</span>
###xml 84 87 <span type="species:ncbi:10376">EBV</span>
###xml 130 133 <span type="species:ncbi:10376">EBV</span>
###xml 452 455 <span type="species:ncbi:10376">EBV</span>
###xml 542 545 <span type="species:ncbi:10376">EBV</span>
Next, we examined if EBV-Z affected the induction of lytic gene expression of KSHV. EBV-Z was transfected into BC3 cells, a KSHV+/EBV- PEL line, and the lytic gene expression of KSHV was examined. Tranfected cells were enriched and split into two wells: one of which was treated by TPA (see Materials and Methods for detail). As shown in the Fig. 5A, the expression of K-RTA and KSHV K8, an early KSHV lytic gene, were inhibited upon the expression of EBV-Z. Due to well-established functions of K-RTA and K8, the results also suggested that EBV-Z inhibited lytic replication of KSHV.
###end p 41
###begin title 42
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
EBV-Z inhibits KSHV lytic gene expression.
###end title 42
###begin p 43
###xml 3 6 <span type="species:ncbi:10376">EBV</span>
###xml 57 60 <span type="species:ncbi:10376">EBV</span>
###xml 125 128 <span type="species:ncbi:10376">EBV</span>
###xml 344 347 <span type="species:ncbi:10376">EBV</span>
###xml 594 597 <span type="species:ncbi:10376">EBV</span>
###xml 688 691 <span type="species:ncbi:10376">EBV</span>
###xml 816 819 <span type="species:ncbi:10376">EBV</span>
###xml 1090 1093 <span type="species:ncbi:10376">EBV</span>
###xml 1179 1182 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1245 1248 <span type="species:ncbi:10376">EBV</span>
###xml 1440 1443 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1506 1509 <span type="species:ncbi:10376">EBV</span>
A. EBV-Z inhibits KSHV lytic gene expression. BC3 (KSHV+/EBV-) cells were transfected with CD4 expressing plasmid along with EBV-Z or vector plasmids. The transfected cells were isolated and equally split into two wells: one well of the cells was treated with TPA for 24 hours. Cell lysates were used for western blot analysis. B. Schematic of EBV-Z functional domains and mutants. The activation domain, basic region (DNA binding domain), leucine zipper region (LZ), and a region of unknown structure at the C terminus (CT) are shown. The drawing is not on scale. In Panels C, D, and E, 293T (EBV-/KSHV-) cells were transfected with various expression plasmids as shown on the top. FLAG-EBV-Z, and its mutants were used. Cell extracts from these transfected cells were immunoprecipitated with either anti-FLAG (for EBV-Z) (Panel C) or anti-K-RTA (Panel D). The immunoprecipitates were analyzed by Western blot using the indicated antibodies. In Panel E, whole cell lysate was used for western blot analyses. The identity of the respective proteins is denoted. In Panels F, G, and H, 293T (EBV-/KSHV-) cells were used. Panel F, KSHV Pan-promoter reporter construct (Pan-luc) and CMV-beta-gal expression plasmid were cotransfected with 400 ng of EBV-Z or its mutant expression plasmids, together with 0, 20, 50 ng of K-RTA expression plasmids respectively as shown on the top. In Panel G, KSHV K14-promoter reporter construct (K14A-luc) and CMV-beta-gal expression plasmid were cotransfected with 100 ng of EBV-Z or its mutant expression plasmids, together with 0, 10, 20 ng of K-RTA expression plasmids respectively as shown on the top. Luciferase activity was normalized by beta -galactosidase activity. The relative folds of activation of promoter constructs are shown with standard deviations. One representative of three independent experiments is shown. Panel H, cell lysates from Panel F were used for western blot analysis. The same membrane was stripped and reprobed with other antibodies. The identity of proteins is as shown.
###end p 43
###begin title 44
###xml 28 31 <span type="species:ncbi:10376">EBV</span>
Interaction is required for EBV-Z-mediated inhibition of K-RTA transactivation
###end title 44
###begin p 45
###xml 85 92 85 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Fig. 5B</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Flemington2">[78]</xref>
###xml 16 19 <span type="species:ncbi:10376">EBV</span>
###xml 155 158 <span type="species:ncbi:10376">EBV</span>
###xml 221 224 <span type="species:ncbi:10376">EBV</span>
###xml 331 334 <span type="species:ncbi:10376">EBV</span>
###xml 398 401 <span type="species:ncbi:10376">EBV</span>
We suspect that EBV-Z uses its leucine zipper domain for the interaction with K-RTA (Fig. 5B). The deletion mutant of leucine zipper (LZ) domain was made (EBV-Z-LD). In addition, another point mutation within the domain (EBV-Z-L214D) was also made because the specific mutation was known to block the dimerization and functions of EBV-Z [78]. Both mutants are localized in the nucleus as wild type EBV-Z (data not shown).
###end p 45
###begin p 46
###xml 237 247 237 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Fig 5C, 5D</xref>
###xml 308 315 308 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Fig. 5E</xref>
###xml 24 27 <span type="species:ncbi:10376">EBV</span>
###xml 120 123 <span type="species:ncbi:10376">EBV</span>
###xml 170 173 <span type="species:ncbi:10376">EBV</span>
###xml 183 186 <span type="species:ncbi:10376">EBV</span>
###xml 353 356 <span type="species:ncbi:10376">EBV</span>
The plasmids expressing EBV-Z or its mutants along with K-RTA were transfected into 293T cells. The interaction between EBV mutants and K-RTA was examined. Both mutants, EBV-Z-LD and EBV-Z-L214D failed to interact with K-RTA as shown in Fig 5C, 5D. The expression of these proteins in 293T cells was proper (Fig. 5E). Thus, the leucine zipper domain of EBV-Z, and Leucine 214 in particular, was involved in the interaction with K-RTA.
###end p 46
###begin p 47
###xml 325 337 325 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Figs. 5F, 5G</xref>
###xml 405 412 405 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Fig. 5H</xref>
###xml 27 30 <span type="species:ncbi:10376">EBV</span>
###xml 219 222 <span type="species:ncbi:10376">EBV</span>
###xml 253 256 <span type="species:ncbi:10376">EBV</span>
###xml 365 368 <span type="species:ncbi:10376">EBV</span>
###xml 376 379 <span type="species:ncbi:10376">EBV</span>
###xml 469 472 <span type="species:ncbi:10376">EBV</span>
Next, we examined if these EBV-Z mutants could affect the functions of K-RTA. KSHV Pan and K14 promoter reporter constructs are potently regulated by K-RTA, and the transactivation was inhibited by the co-expression of EBV-Z. However, the expression of EBV-Z mutants failed to repress the transactivation functions of K-RTA (Figs. 5F, 5G). The expression of K-RTA, EBV-Z, and EBV-Z mutants was confirmed (Fig. 5H). These data suggested that the interaction between the EBV-Z and K-RTA was required for the inhibition of K-RTA mediated transactivation.
###end p 47
###begin title 48
###xml 74 77 <span type="species:ncbi:10376">EBV</span>
Initiation of KSHV lytic gene expression correlated with the reduction of EBV lytic gene expression
###end title 48
###begin p 49
###xml 6 9 <span type="species:ncbi:10376">EBV</span>
###xml 38 41 <span type="species:ncbi:10376">EBV</span>
BC-1 (EBV+, KSHV+) is known to induce EBV lytic replication upon the treatment of TPA. We have tested if we could change the outcomes of the lytic gene expression by alternation of TPA dosages.
###end p 49
###begin p 50
###xml 820 826 820 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Fig 6A</xref>
###xml 864 873 864 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g001">Figures 1</xref>
###xml 878 879 878 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g002">2</xref>
###xml 98 101 <span type="species:ncbi:10376">EBV</span>
###xml 173 176 <span type="species:ncbi:10376">EBV</span>
###xml 261 264 <span type="species:ncbi:10376">EBV</span>
###xml 312 315 <span type="species:ncbi:10376">EBV</span>
###xml 493 496 <span type="species:ncbi:10376">EBV</span>
###xml 650 653 <span type="species:ncbi:10376">EBV</span>
###xml 677 680 <span type="species:ncbi:10376">EBV</span>
###xml 740 743 <span type="species:ncbi:10376">EBV</span>
###xml 933 936 <span type="species:ncbi:10376">EBV</span>
BC1 cells were treated with different concentration of TPA, and the lytic gene expression of both EBV and KSHV were analyzed simultaneously. At low level of TPA treatments, EBV lytic gene expression was induced as indicated by the expression of EA-D as well as EBV-Z. However, at higher levels of TPA treatment, EBV lytic gene expression was turned down. Coincidently, the KSHV lytic gene expression was initiated as indicated by the expression of K-RTA and K-8. Thus, TPA could induce either EBV or KSHV lytic gene expression in BC cells depending on the dosages. More importantly, the KSHV lytic gene expression apparently correlated with dampened EBV lytic gene expression. EBV-Z was induced in a dose dependent manner. At TPA 20 ng/ml, EBV-Z was expressed at the highest levels, but the EA-D expression was dropped (Fig 6A; bottom panel). Based on the data in Figures 1 and 2, the expression of K-RTA might block the function of EBV-Z, which reduced the EA-D levels. Furthermore, the excess K-RTA might activate KSHV lytic replication as determined by KSHV K8 expression. It is of note that although different batches of TPA had different dose response curves, the general trend was the same even with TPAs from different companies (data not shown).
###end p 50
###begin title 51
###xml 74 77 <span type="species:ncbi:10376">EBV</span>
Initiation of KSHV lytic gene expression correlated with the reduction of EBV lytic gene expression.
###end title 51
###begin p 52
###xml 22 25 <span type="species:ncbi:10376">EBV</span>
###xml 58 61 <span type="species:ncbi:10376">EBV</span>
###xml 362 365 <span type="species:ncbi:10376">EBV</span>
###xml 369 372 <span type="species:ncbi:10376">EBV</span>
###xml 430 433 <span type="species:ncbi:10376">EBV</span>
A. TPA induces either EBV or KSHV lytic replication. BC1 (EBV+/KSHV+) cells were treated with TPA at indicated dosages shown on the top. Cell lysates were used for western blot analyses a day later. The same membrane was stripped and reprobed with other antibodies. The identity of proteins is as shown. The relative levels of EA-D expression (EA-D/Tubulin) and EBV-Z (EBV-Z/Tubulin) were obtained by measuring intensity of EA-D, EBV-Z, and Tubulin using ImageJ 1.37v software (NIH), and are shown on the bottom panels. One representative from three independent experiments is shown. B. Kinetics of K-RTA expression in BC1 cells. BC1 cells were treated with TPA (20 ng/ml), or butyrate (3 mM), or both. Total RNA were isolated at indicated time post treatment. The expression of K-RTA and GAPDH RNA was monitored by RPA with K-RTA and GADPH probes simultaneously. Specific protections of K-RTA and GAPDH RNAs are indicated. The relative levels of K-RTA RNA expression (K-RTA/GAPDH) were obtained by measuring intensity of K-RTA and GAPDH using ImageJ 1.37v software (NIH), and are shown on the bottom. One representative from three independent experiments is shown.
###end p 52
###begin p 53
###xml 174 181 174 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Fig. 6B</xref>
Finally, we examined kinetics of the K-RTA RNA expression under different induction conditions. BC1 cells were treated with different kinds of chemical inducers. As shown in Fig. 6B, butyrate or butyrate plus TPA could induce significant K-RTA RNA after 1-2 hours of treatments; however, TPA was able to induce the similar levels of expression only after 6 hours of the treatment. Thus comparing to butyrate or TPA plus butyrate, treatment with TPA induces delayed expression of K-RTA RNA in BC1 cells.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Fan1">[49]</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Xu1">[52]</xref>
###xml 594 598 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Trivedi1">[48]</xref>
###xml 248 251 <span type="species:ncbi:10376">EBV</span>
The mechanisms of latency and lytic replications of gamma herpesviruses are extensively studied. The induction processes of lytic replications are apparently heterogeneous and depend on the cell, virus, and inducing agent. The co-existance of both EBV and KSHV in majority of PELs is providing a unique opportunity to study the interaction between the two viruses and the potential role in the pathogenesis. The two viruses are apparently able to interact with each other as well as the host [49]-[52], and the presence of both viruses is more potent to promote tumor formation in rodent model [48].
###end p 55
###begin p 56
###xml 264 270 264 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3</xref>
###xml 346 352 346 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g001">Fig. 1</xref>
###xml 463 469 463 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g002">Fig. 2</xref>
###xml 649 656 649 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g002">Fig. 2C</xref>
###xml 849 856 849 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Fig. 5A</xref>
###xml 947 957 947 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">Fig. 5B&#8211;5H</xref>
###xml 1088 1095 1088 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g004">Figs. 4</xref>
###xml 1100 1101 1100 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">5</xref>
###xml 1266 1273 1266 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g004">Figs. 4</xref>
###xml 1278 1279 1278 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g005">5</xref>
###xml 1409 1415 1409 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Fig. 6</xref>
###xml 1826 1833 1826 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3A</xref>
###xml 1896 1904 1896 1904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Figure 6</xref>
###xml 101 104 <span type="species:ncbi:10376">EBV</span>
###xml 152 155 <span type="species:ncbi:10376">EBV</span>
###xml 319 322 <span type="species:ncbi:10376">EBV</span>
###xml 421 424 <span type="species:ncbi:10376">EBV</span>
###xml 472 475 <span type="species:ncbi:10376">EBV</span>
###xml 537 540 <span type="species:ncbi:10376">EBV</span>
###xml 595 598 <span type="species:ncbi:10376">EBV</span>
###xml 735 738 <span type="species:ncbi:10376">EBV</span>
###xml 773 776 <span type="species:ncbi:10376">EBV</span>
###xml 900 903 <span type="species:ncbi:10376">EBV</span>
###xml 1011 1014 <span type="species:ncbi:10376">EBV</span>
###xml 1181 1184 <span type="species:ncbi:10376">EBV</span>
###xml 1382 1385 <span type="species:ncbi:10376">EBV</span>
###xml 1456 1459 <span type="species:ncbi:10376">EBV</span>
###xml 1590 1593 <span type="species:ncbi:10376">EBV</span>
###xml 1762 1765 <span type="species:ncbi:10376">EBV</span>
###xml 1924 1927 <span type="species:ncbi:10376">EBV</span>
###xml 1995 1998 <span type="species:ncbi:10376">EBV</span>
In this report, we have provided evidence that the critical lytic replication initiators of KSHV and EBV interact at molecular levels. First, K-RTA and EBV-Z are co-localized, and the two proteins physically interact with each other in the same PEL cells in vivo (Fig. 3). Second, K-RTA inhibits the chemically-induced EBV lytic gene expression (Fig. 1), and the inhibition may be related to the fact that K-RTA inhibits EBV-Z mediated lytic replication process (Fig. 2). EBV-Z and R-RTA physically interact and synergistically activate EBV lytic gene expression. This synergistic activation of EBV lytic gene expression is also inhibited by K-RTA (Fig. 2C), which clear shows the functional difference between K-RTA and E-RTA. Third, EBV-Z has the similar effect on KSHV: EBV-Z inhibits the chemically-induced KSHV lytic gene expression processes (Fig. 5A), and the inhibition is likely due to that EBV-Z inhibits K-RTA-mediated transactivation (Fig. 5B-5H). Fourth, the physical interaction between K-RTA and EBV-Z is apparently required for the mutual inhibition of the two molecules (Figs. 4 and 5). The leucine heptapeptide repeat region in K-RTA and leucine zipper region in EBV-Z molecules are involved in the physical interactions between the two molecules (Figs. 4 and 5). Fifth, we have shown that initiation of KSHV lytic gene expression correlated with the reduction of EBV lytic gene expression (Fig. 6). All these data suggest that K-RTA and EBV-Z are physically interact and mutually inhibits each others' functions. However, we cannot exclude the possibility that K-RTA and EBV-Z proteins are interacting indirectly through other proteins, and we are investigating the subject currently. Finally, dually infected cells can express both K-RTA and EBV-Z in the same cells under the special induction conditions (Fig. 3A). Of note under routine induction conditions such as shown in Figure 6, immunostaining of EBV-Z and K-RTA showed that the majority of cells were either K-RTA or EBV-Z positive, and only a small fraction were positive for both (data not shown). All these data collectively indicate that the physical interaction between the two proteins is relevant to the control of lytic gene expression in dually infected cells.
###end p 56
###begin p 57
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Bu1">[75]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Sinclair1">[79]</xref>
###xml 99 102 <span type="species:ncbi:10376">EBV</span>
The mechanism of the mutual inhibition is not completely clear yet. However because both K-RTA and EBV-Z require multimerization for their proper functions [75], [79], we suspect that the physical interactions between the two may affect their respective multimerization process and thus inhibit each others' function.
###end p 57
###begin p 58
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Sun2">[12]</xref>
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Miller1">[53]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Miller1">[53]</xref>
###xml 351 354 <span type="species:ncbi:10376">EBV</span>
###xml 416 419 <span type="species:ncbi:10376">EBV</span>
###xml 472 475 <span type="species:ncbi:10376">EBV</span>
###xml 651 654 <span type="species:ncbi:10376">EBV</span>
###xml 680 683 <span type="species:ncbi:10376">EBV</span>
###xml 1051 1054 <span type="species:ncbi:10376">EBV</span>
There is an interesting phenomenon referred as selective switch from latency to lytic replication in dually infected cells [12], [53]. The mechanisms behind the selective induction of lytic replication is unknown, but the phenomenon clearly suggests that viral factor(s) is involved in this selective induction [53]. Based on the facts that K-RTA and EBV-Z are the critical lytic replication initiators for KSHV and EBV latencies respectively, and our data that K-RTA and EBV-Z mutually inhibit each other's transactivations, we hypothesize that various chemical treatments and/or physiological stimuli may trigger differential expression of K-RTA or EBV-Z. The induced K-RTA and EBV-Z would neutralize each others' function through physical interactions. The predominantly-expressed gene product would block the function of another less-expressed one in dually infected cells. This process would result in only one critical lytic replication initiator remains functional in dually-infected PELs. The predominantly expressed molecule, either K-RTA or EBV-Z, would lead to the selective lytic replication of one virus in dually-infected PELs. The selective induction of lytic replication may facilitate the survival of the winning virus by maximally utilizing cellular resources.
###end p 58
###begin p 59
###xml 217 223 217 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Fig. 6</xref>
###xml 340 347 340 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Fig. 6A</xref>
###xml 530 537 530 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Fig. 6B</xref>
###xml 706 713 706 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g006">Fig. 6B</xref>
###xml 978 982 978 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Ye1">[80]</xref>
###xml 50 53 <span type="species:ncbi:10376">EBV</span>
###xml 190 193 <span type="species:ncbi:10376">EBV</span>
###xml 290 293 <span type="species:ncbi:10376">EBV</span>
###xml 408 411 <span type="species:ncbi:10376">EBV</span>
###xml 623 626 <span type="species:ncbi:10376">EBV</span>
###xml 795 798 <span type="species:ncbi:10376">EBV</span>
###xml 886 889 <span type="species:ncbi:10376">EBV</span>
###xml 1063 1066 <span type="species:ncbi:10376">EBV</span>
However, KSHV is apparently has an advantage over EBV on the selective lytic replication processes. First, that the initiation of KSHV lytic gene expression correlated with the reduction of EBV lytic gene expression (Fig. 6) suggests that the presence of KSHV lytic genes is overriding the EBV lytic gene expressions at least in BC1 cells (Fig. 6A). Second, TPA has been shown to induce lytic replication of EBV in BC1 cells. We have found that TPA induces delayed expression of K-RTA, comparing to butyrate or TPA plus butyrate (Fig. 6B). The delayed induction of K-RTA may provide an opportunity for lytic replication of EBV in BC1 cells. In addition, the faster induction of K-RTA by TPA plus butyrate (Fig. 6B) provides an explanation that TPA and butyrate together induce KSHV, rather than EBV, lytic replication in BC1 cells. Third and finally, the induction of expression of the EBV-Z and E-RTA needs de novo protein synthesis while the induction of K-RTA of KSHV is not [80]. Therefore with all available data, KSHV is apparently having an advantage over EBV for the induction of lytic replication in dually infected PELs.
###end p 59
###begin p 60
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Miller1">[53]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Xu1">[52]</xref>
###xml 54 57 <span type="species:ncbi:10376">EBV</span>
###xml 392 395 <span type="species:ncbi:10376">EBV</span>
###xml 487 490 <span type="species:ncbi:10376">EBV</span>
It is of note that the mutual inhibition of K-RTA and EBV-Z may be used by both viruses to maintain and/or establish dual latency in PELs. The dually infected cells are apparently more latent [53]. The mutual inhibition of the two lytic initiators may block some spontaneous lytic replications. In addition, the during primary infection processes to establish the dual latency, both KSHV and EBV lytic gene expressions are likely to be initiated [52]. The mutual inhibition of K-RTA and EBV-Z might play a role for the establishment of dual latency in the same cells in primary infection.
###end p 60
###begin p 61
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Xu1">[52]</xref>
###xml 31 34 <span type="species:ncbi:10376">EBV</span>
###xml 83 86 <span type="species:ncbi:10376">EBV</span>
###xml 127 130 <span type="species:ncbi:10376">EBV</span>
###xml 191 194 <span type="species:ncbi:10376">EBV</span>
###xml 287 290 <span type="species:ncbi:10376">EBV</span>
###xml 326 329 <span type="species:ncbi:10376">EBV</span>
###xml 384 387 <span type="species:ncbi:10376">EBV</span>
###xml 434 437 <span type="species:ncbi:10376">EBV</span>
Our previous data suggest that EBV inhibits the lytic replication of both KSHV and EBV through another mechanism involved with EBV latent membrane protein 1 [52]. The general consequences of EBV-Z or LMP-1-mediated inhibition of KSHV lytic replication are different: LMP-1 inhibits both EBV and KSHV lytic replications, while EBV-Z only inhibits KSHV lytic replication, but initiates EBV lytic replication. The comparative studies of EBV-Z and LMP-1 for their inhibitory effects on KSHV lytic replication have not been carried out extensively. However, the new mechanism identified in this report may reinforce the point that two viruses would prefer to maintain respective latency in a dually infected cells. One explanation would be that the lytic replication of the viruses may lead to the eventual death of the host cells. Therefore, both viruses may use their interactions to block potential lytic replication inductions.
###end p 61
###begin p 62
###xml 234 237 234 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e</italic>
###xml 391 394 <span type="species:ncbi:10376">EBV</span>
###xml 413 416 <span type="species:ncbi:10376">EBV</span>
###xml 598 601 <span type="species:ncbi:10376">EBV</span>
In summary, we have addressed how the two viruses interact with each other in dually infected PELs. Our data may provided a possible mechanism for maintaining viral latency and for selective lytic replication in dually infected PELs, i.e., through mutual inhibition of two critical lytic replication initiators. Of note, the majority of the current studies on lytic replications of KSHV and EBV are using KSHV or EBV single-infected cells as model systems. Therefore, there is a concern about the applicability of these studies in dually-infected PELs. Our data about putative interactions between EBV and KSHV would be applicable to the majority of AIDS-associated PELs and may be relevant to the pathogenesis of PELs.
###end p 62
###begin title 63
Materials and Methods
###end title 63
###begin title 64
Plasmids and antibodies
###end title 64
###begin p 65
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Zhang1">[18]</xref>
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Xu1">[52]</xref>
###xml 320 370 320 370 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCACCGGCAAGGTCACTGGAAGCCAGTTTGTCATTAGCAAACCC-3&#8242;</named-content>
###xml 510 563 510 563 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCGGGCCAAGTTTAAGCAACTGTGCCCAAGCCTGGATGTTGACTCC-3&#8242;</named-content>
###xml 681 733 681 733 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAAATCATCTGAAAATGACAGGGATCGCCTCCTGTTGAAGCAGATG-3&#8242;</named-content>
###xml 941 945 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Xu1">[52]</xref>
###xml 7 10 <span type="species:ncbi:10376">EBV</span>
###xml 108 111 <span type="species:ncbi:10376">EBV</span>
###xml 655 658 <span type="species:ncbi:10376">EBV</span>
###xml 662 665 <span type="species:ncbi:10376">EBV</span>
###xml 797 800 <span type="species:ncbi:10376">EBV</span>
###xml 821 824 <span type="species:ncbi:10376">EBV</span>
###xml 835 838 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 982 985 <span type="species:ncbi:10376">EBV</span>
###xml 1108 1111 <span type="species:ncbi:10376">EBV</span>
###xml 1271 1277 <span type="species:ncbi:9793">donkey</span>
###xml 1283 1288 <span type="species:ncbi:10090">mouse</span>
###xml 1326 1332 <span type="species:ncbi:9793">donkey</span>
###xml 1338 1344 <span type="species:ncbi:9986">rabbit</span>
K-RTA, EBV-Z and E-RTA expression plasmids, K14A-luc and Pan-luc were described previously [18], [52]. Flag-EBV-Z expression plasmid was a gift from Dr. Paul Lieberman. The mutant plasmids were made with the proper primers and the use of Quick Change II Site-Directed Mutagenesis Kit (Stratagene). The oligonucleotides, 5'-CCACCGGCAAGGTCACTGGAAGCCAGTTTGTCATTAGCAAACCC-3' and its complementary strand were used for deletion of the leucine heptapeptide repeat (LR) (a.a.# 246-292) in K-RTA (K-RTA-DLR). Primers, 5'-GCCGGGCCAAGTTTAAGCAACTGTGCCCAAGCCTGGATGTTGACTCC-3' and its complement strand were used to delete the leucine zipper region (a.a.# 197-221) of EBV-Z (EBV-Z-DL). Primes, 5'-CAAATCATCTGAAAATGACAGGGATCGCCTCCTGTTGAAGCAGATG-3' and its complement were used to change leucine at a.a. #214 of EBV-Z to aspartic acid (EBV-Z-L214D). CMV-beta-galactosidase expression plasmid was from Clontech. Peptide antibody against K-RTA was described [52]. K8 antibody was from Dr. Jae Jung. EBV-Z monoclonal antibody (BZ1; sc-53904) and GAPDH (sc-47724) were purchased from Santa Cruz Biotechnology. Monoclonal EA-D (EBV-018-48180) was from Capricorn. E-RTA (11-008) antibody was from Argene. FLAG (F3165) and Tubulin (T6557) antibodies were purchased from Sigma. Cy-2-conjugated donkey anti-mouse IgG (715-225-150) and Cy5-conjugated donkey anti-rabbit IgG (711-175-152) antibodies were purchased from Jackson ImmunoResearch Laboratory.
###end p 65
###begin title 66
Cell Culture and Recombinant Adenovirus Infection
###end title 66
###begin p 67
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Cesarman1">[81]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Arvanitakis1">[82]</xref>
###xml 281 285 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Feederle1">[38]</xref>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Feederle1">[38]</xref>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Borza1">[83]</xref>
###xml 745 749 745 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Seaman1">[84]</xref>
###xml 7 10 <span type="species:ncbi:10376">EBV</span>
###xml 39 42 <span type="species:ncbi:10376">EBV</span>
###xml 60 63 <span type="species:ncbi:10376">EBV</span>
###xml 159 162 <span type="species:ncbi:10376">EBV</span>
###xml 174 179 <span type="species:ncbi:9606">human</span>
###xml 205 208 <span type="species:ncbi:10376">EBV</span>
###xml 271 274 <span type="species:ncbi:10376">EBV</span>
###xml 400 403 <span type="species:ncbi:10376">EBV</span>
###xml 542 545 <span type="species:ncbi:10376">EBV</span>
###xml 991 994 <span type="species:ncbi:10376">EBV</span>
Akata (EBV+,KSHV-) is an BL line. BC1 (EBV+,KSHV+) and BC3 (EBV-, KSHV+) are PEL lines [81], [82]. These cells were maintained in RPMI1640 plus 10% FBS. 293T (EBV-,KSHV-) is human fibroblast line. 293EBV (EBV+, KSHV-) is a 293 fibroblast derived cell line with wild type EBV genome[38]. BRLF1KO and BZLF1KO were also 293 fibroblast derived cell lines with BRLF1 or BZLF1 deletion in their respective EBV genomes [38]. These three lines were maintained in DMEM plus 10% FBS plus 0.5 mg/ml hygromycin. AGS-BX11g is an epithelial cell line with EBV genome and was maintained in DMEM plus 10% FBS plus 0.5 mg/ml G418 [83]. The recombinant adenovirus for green fluorescence protein (GFP) (AdGFP) and K-RTA (AdRTA) were a gift from Dr. Byrd Quinlivan [84]. The recombinant adenoviruses were titered in 293 cells. AGS-BX11g cells were infected by recombinant viruses at a multiplicity of infection (MOI) of 10 (calculated from PFU). One day later, cells were then treated with TPA for induction of EBV lytic replication.
###end p 67
###begin title 68
Induction of lytic replication
###end title 68
###begin p 69
###xml 3 4 3 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 431 437 431 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001569-g003">Fig. 3</xref>
###xml 251 255 <span type="species:ncbi:9925">Goat</span>
###xml 261 266 <span type="species:ncbi:9606">human</span>
###xml 298 301 <span type="species:ncbi:9685">Cat</span>
###xml 332 335 <span type="species:ncbi:10376">EBV</span>
12-O-tetradecanoylphorbol-13-acetate (TPA; from Sigma or Aldrich) was used to treat BC3 (5-10 ng/ml), BC1 (1-40 ng/ml), and AGS-BX11g (0.5-2 ng/ml) for induction of lytic replication. Sodium butyrate was also used for induction of lytic replications. Goat anti-human immunoglobulin G (IgG) (Sigma; Cat# I-9384) was used to activate EBV lytic replication in Akata cells. For immunostaining and co-immunoprecipitation experiments in Fig. 3, BC1 cells were treated with 10 ng/ml TPA overnight, and then treated with butyrate (0.5 mM). The cells were collected a day later for immunostaining and immunoprecipitation experiments.
###end p 69
###begin title 70
Transient Transfection, Isolation of Transfected cells, and Reporter Assays
###end title 70
###begin p 71
###xml 228 229 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 555 559 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Zhang3">[85]</xref>
###xml 560 564 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Zhang5">[87]</xref>
###xml 1110 1111 1090 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 343 348 <span type="species:ncbi:9606">human</span>
Effectene (Qiagen) was used for the transfection of 293EBV, BRLF1-KO, BZLF1KO and 293T cells. Transfection of Akata cells were achieved by using Amaxa Nucleofector Device. Briefly, 5 microg of plasmids were transfected into 2x106 cells in 100 microl solution V using program G016. Six hours later, the transfected cells were treated with anti-human-IgG. Transfection efficiency was about 70%. Electroporation (320V; 925 microF) was used for transfection of BC3 cells and the selection of transfected cells was essentially the same as described previously [85]-[87]. CD4 and other expression plasmids were transfected into BC3 cells. One day after the transfection, the cells were used for isolation of CD4-positive cells with the use of Dynabeads CD4 (Dynal Inc). The enriched cells were detached from the Dynabeads CD4 by incubation for 45-60 minutes at room temperature with 10 microl of DETACHaBEAD (Dynal). The detached beads were removed by using a magnet separation device. The released cells were washed 2-3 times with 500 microl RPMI 1640 plus 10% FBS, and resuspended in RPMI 1640 plus 10% FBS at 5x105 cells/ml. Cells were split into two wells and recovered for 2-6 hours: TPA (5 ng/ml) were added into one well. The treated cells were collected one day later. The luciferase assays were performed using the assay kit from Promega according to manufacturer's recommendation.
###end p 71
###begin title 72
Western Blot Analysis, RNA extraction, and RNase Protection Assays (RPA)
###end title 72
###begin p 73
###xml 58 62 58 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Zhang6">[88]</xref>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001569-Zhang5">[87]</xref>
Standard western blot analysis was performed as described [88]. Total RNA was isolated from cells using the RNeasy Total RNA Isolation Kit (Qiagen). RPA was performed with total RNA using the RNase Protection Assay Kit II (Ambion) as described [87]. The GAPDH probe was from US Biochemicals, Inc. The probe for K-RTA was made by PCR of the K-RTA region (BC1 coordinates: 72601-72900) followed by cloning into pcDNA3 vector.
###end p 73
###begin title 74
Co-immunoprecipitation (Co-IP)
###end title 74
###begin p 75
###xml 611 617 <span type="species:ncbi:9986">rabbit</span>
###xml 621 626 <span type="species:ncbi:10090">mouse</span>
BC-1 cells were treated with 10 ng TPA per ml for 24 h, and with 0.5 mM sodium butyrate for another 24 h. 293T cells grown in 10-cm plates were transfected with the designated plasmids, and cells were ready for experiments 24 hours later. These cells were washed with PBS and lysed at 4degreesC for 30 min in EBC buffer (50 mM Tris-HCl, pH7.5, 120 mM NaCl, 0.5% NP-40) supplemented with protease inhibitor cocktail tablet (Roche) with gentle rotation. The cell lysates were centrifuged at 16,100xg for 15 min, and the supernatants were recovered. For coimmunoprecipitation, lysates were pre-cleared with normal rabbit or mouse IgG with 20 ml Protein G Sepharose. Specific antibodies and Protein G Sepharose (GE Healthcare) at 4degreesC for 1hour or overnight. The beads were washed three times with EBC buffer, boiled in SDS loading buffer, and subsequent Western blot were essentially the same as described.
###end p 75
###begin title 76
Immunochemical analysis
###end title 76
###begin p 77
###xml 372 375 <span type="species:ncbi:10376">EBV</span>
###xml 557 562 <span type="species:ncbi:10090">mouse</span>
###xml 623 629 <span type="species:ncbi:9986">rabbit</span>
The TPA and butyrate treated BC1 cells were centrifuged and washed with phosphate-buffered saline solution (PBS), and fixed with 4% paraformaldehyde for 15 minutes. The cells were permeabilized with 100% cold methanol for 5 minutes. After washing with PBS, the cells were blocked with PBST including 1% BSA for 30 minutes. The cells were incubated with antibodies against EBV-Z (1:50 dilution) and K-RTA (1:50 dilution) for one hour. Following three washing with PBST, the cells were incubated for one hour with Cy-2 conjugated secondary antibodies against mouse IgG (1:60) and Cy5 -conjugated secondary antibodies against rabbit IgG (1:60). Finally, DAPI was used for nuclei staining and the cells were mounted (Gel Mount Aqueous Mounting Medium, Sigma) in the poly-prep slides (Sigma) for analysis with confocal microscopy (Olympus FV500) in the Microscopy Core facility at the University of Nebraska-Lincoln.
###end p 77
###begin p 78
We thank Drs. Paul Lieberman, Henri-Jacques Delecluse, Jae Jung, Lindsey Hutt-Flectcher, and Byrd Quinlivan for providing reagents for this work; Dr. Clinton Jones for critical reading of the manuscript; UNL Microscopy and Sequencing Facility for their assistance.
###end p 78
###begin title 79
References
###end title 79
###begin article-title 80
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus and its replication.
###end article-title 80
###begin article-title 81
Epstein-Barr Virus.
###end article-title 81
###begin article-title 82
###xml 16 34 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Pathogenesis of Epstein-Barr virus and its associated malignancies.
###end article-title 82
###begin article-title 83
Epstein-Barr Virus.
###end article-title 83
###begin article-title 84
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Epstein-Barr virus: the first human tumor virus and its role in cancer.
###end article-title 84
###begin article-title 85
Kaposi's Sacrcoma-Associated Herpesvirus.
###end article-title 85
###begin article-title 86
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
###end article-title 86
###begin article-title 87
Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS.
###end article-title 87
###begin article-title 88
###xml 52 57 <span type="species:ncbi:9606">human</span>
The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression.
###end article-title 88
###begin article-title 89
###xml 63 68 <span type="species:ncbi:9606">human</span>
Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.
###end article-title 89
###begin article-title 90
Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.
###end article-title 90
###begin article-title 91
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.
###end article-title 91
###begin article-title 92
Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.
###end article-title 92
###begin article-title 93
Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression.
###end article-title 93
###begin article-title 94
Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus.
###end article-title 94
###begin article-title 95
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line.
###end article-title 95
###begin article-title 96
Transcription mapping and expression patterns of genes in the major immediate-early region of Kaposi's sarcoma-associated herpesvirus.
###end article-title 96
###begin article-title 97
###xml 40 45 <span type="species:ncbi:9606">Human</span>
Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 Replication and Transcription Activator Regulates Viral and Cellular Genes via Interferon-Stimulated Response Elements.
###end article-title 97
###begin article-title 98
Identification of a cellular protein that interacts and synergizes with the RTA (ORF50) protein of Kaposi's sarcoma-associated herpesvirus in transcriptional activation.
###end article-title 98
###begin article-title 99
CREB-binding protein and histone deacetylase regulate the transcriptional activity of Kaposi's sarcoma-associated herpesvirus open reading frame 50.
###end article-title 99
###begin article-title 100
Kaposi's Sarcoma-associated herpesvirus open reading frame 50 stimulates the transcriptional activity of STAT3.
###end article-title 100
###begin article-title 101
###xml 50 69 <span type="species:ncbi:37296">human herpesvirus 8</span>
K-bZIP of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) binds KSHV/HHV-8 Rta and represses Rta-mediated transactivation.
###end article-title 101
###begin article-title 102
The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway.
###end article-title 102
###begin article-title 103
Lytic but not latent infection by Kaposi's sarcoma-associated herpesvirus requires host CSL protein, the mediator of Notch signaling.
###end article-title 103
###begin article-title 104
###xml 11 30 <span type="species:ncbi:37296">human herpesvirus 8</span>
###xml 82 87 <span type="species:ncbi:9606">human</span>
Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression.
###end article-title 104
###begin article-title 105
Kaposi's sarcoma-associated herpesvirus open reading frame 50 represses p53-induced transcriptional activity and apoptosis.
###end article-title 105
###begin article-title 106
Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency.
###end article-title 106
###begin article-title 107
Activation of the Kaposi's sarcoma-associated herpesvirus major latency locus by the lytic switch protein RTA (ORF50).
###end article-title 107
###begin article-title 108
Activation of CD21 and CD23 gene expression by Kaposi's sarcoma-associated herpesvirus RTA.
###end article-title 108
###begin article-title 109
###xml 5 23 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 25 28 <span type="species:ncbi:10376">EBV</span>
###xml 120 123 <span type="species:ncbi:10376">EBV</span>
Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.
###end article-title 109
###begin article-title 110
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.
###end article-title 110
###begin article-title 111
###xml 21 24 <span type="species:ncbi:10376">EBV</span>
The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper.
###end article-title 111
###begin article-title 112
###xml 3 21 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 92 120 <span type="species:ncbi:12721">human immunodeficiency virus</span>
An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.
###end article-title 112
###begin article-title 113
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
###xml 86 104 <span type="species:ncbi:10376">Epstein-Barr virus</span>
In Vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein.
###end article-title 113
###begin article-title 114
The Zta-trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction.
###end article-title 114
###begin article-title 115
###xml 79 97 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions.
###end article-title 115
###begin article-title 116
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional transactivators.
###end article-title 116
###begin article-title 117
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.
###end article-title 117
###begin article-title 118
###xml 100 118 <span type="species:ncbi:10376">Epstein-Barr virus</span>
G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta.
###end article-title 118
###begin article-title 119
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.
###end article-title 119
###begin article-title 120
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
###end article-title 120
###begin article-title 121
Lytic but not latent replication of epstein-barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins.
###end article-title 121
###begin article-title 122
###xml 18 36 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Autoregulation of Epstein-Barr virus BZLF1 putative lytic switch gene BZLF1.
###end article-title 122
###begin article-title 123
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites.
###end article-title 123
###begin article-title 124
###xml 35 40 <span type="species:ncbi:9606">human</span>
Auto-activation of the rta gene of human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus.
###end article-title 124
###begin article-title 125
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.
###end article-title 125
###begin article-title 126
Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas).
###end article-title 126
###begin article-title 127
###xml 71 89 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 110 113 <span type="species:ncbi:10376">EBV</span>
Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression.
###end article-title 127
###begin article-title 128
Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.
###end article-title 128
###begin article-title 129
###xml 120 138 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters.
###end article-title 129
###begin article-title 130
###xml 0 19 <span type="species:ncbi:37296">Human herpesvirus 8</span>
###xml 107 125 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells.
###end article-title 130
###begin article-title 131
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.
###end article-title 131
###begin article-title 132
###xml 91 109 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.
###end article-title 132
###begin article-title 133
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex.
###end article-title 133
###begin article-title 134
###xml 45 63 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Trans-acting requirements for replication of Epstein-Barr virus ori-Lyt.
###end article-title 134
###begin article-title 135
Functional Expression and Characterization of the Epstein-Barr Virus DNA Polymerase Catalytic Subunit.
###end article-title 135
###begin article-title 136
Functional Interaction between Epstein-Barr Virus DNA Polymerase Catalytic Subunit and Its Accessory Subunit In Vitro.
###end article-title 136
###begin article-title 137
Further Characterization of the Interaction between the Epstein-Barr Virus DNA Polymerase Catalytic Subunit and Its Accessory Subunit with Regard to the 3'-to-5' Exonucleolytic Activity and Stability of Initiation Complex at Primer Terminus.
###end article-title 137
###begin article-title 138
###xml 14 32 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
###end article-title 138
###begin article-title 139
###xml 23 41 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 43 46 <span type="species:ncbi:10376">EBV</span>
###xml 95 98 <span type="species:ncbi:10376">EBV</span>
Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.
###end article-title 139
###begin article-title 140
###xml 50 68 <span type="species:ncbi:10376">Epstein-Barr virus</span>
A redox-sensitive cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication.
###end article-title 140
###begin article-title 141
###xml 45 63 <span type="species:ncbi:10376">Epstein-Barr virus</span>
An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators.
###end article-title 141
###begin article-title 142
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 24 27 <span type="species:ncbi:10376">EBV</span>
###xml 89 92 <span type="species:ncbi:10376">EBV</span>
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner.
###end article-title 142
###begin article-title 143
###xml 34 52 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta.
###end article-title 143
###begin article-title 144
Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP.
###end article-title 144
###begin article-title 145
Kaposi's sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: physical association and promoter-dependent transcriptional repression.
###end article-title 145
###begin article-title 146
Cell cycle arrest by Kaposi's sarcoma-associated herpesvirus replication-associated protein is mediated at both the transcriptional and posttranslational levels by binding to CCAAT/enhancer-binding protein alpha and p21(CIP-1).
###end article-title 146
###begin article-title 147
###xml 76 94 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Functional and physical interaction between p53 and BZLF1: Implications for Epstein-Barr virus latency.
###end article-title 147
###begin article-title 148
The Kaposi's sarcoma-associated herpesvirus K8 protein interacts with CREB-binding protein (CBP) and represses CBP-mediated transcription.
###end article-title 148
###begin article-title 149
###xml 90 108 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation.
###end article-title 149
###begin article-title 150
The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity.
###end article-title 150
###begin article-title 151
###xml 105 123 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus.
###end article-title 151
###begin article-title 152
Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha.
###end article-title 152
###begin article-title 153
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.
###end article-title 153
###begin article-title 154
###xml 40 59 <span type="species:ncbi:37296">human herpesvirus 8</span>
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.
###end article-title 154
###begin article-title 155
Kaposi's Sarcoma-associated herpesvirus lytic switch protein stimulates DNA binding of RBP-Jk/CSL to activate the Notch pathway.
###end article-title 155
###begin article-title 156
CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters.
###end article-title 156
###begin article-title 157
###xml 46 64 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Evidence of coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues.
###end article-title 157
###begin article-title 158
###xml 17 22 <span type="species:ncbi:9606">human</span>
bZIP proteins of human gammaherpesviruses.
###end article-title 158
###begin article-title 159
###xml 70 88 <span type="species:ncbi:10376">Epstein-Barr virus</span>
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
###end article-title 159
###begin article-title 160
In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.
###end article-title 160
###begin article-title 161
###xml 184 202 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
###end article-title 161
###begin article-title 162
###xml 74 92 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus.
###end article-title 162
###begin article-title 163
Gene expression from the ORF50/K8 region of Kaposi's sarcoma-associated herpesvirus.
###end article-title 163
###begin article-title 164
###xml 67 85 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Interferon Regulatory Factor 7 mediates the activation of Tap-2 by Epstein-Barr virus latent membrane protein 1.
###end article-title 164
###begin article-title 165
Intracellular signaling molecules activated by Epstein Barr virus for induction of interferon regulatory factor 7.
###end article-title 165
###begin article-title 166
###xml 45 63 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1.
###end article-title 166
###begin article-title 167
Interferon Regulatory Factor 2 Represses the Epstein-Barr Virus BamH I Q Latency Promoter In Type III Latency.
###end article-title 167
###begin p 168
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 168
###begin p 169
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in part by grants from the NIH AI59132, CA108951, and NCRR COBRA grant RR15635 (LZ).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 169

